7VC3
Toxoplasma gondii Prolyl-tRNA Synthetase (TgPRS) in Complex with inhibitor L97 and L-proline at 1.97 A resolution
Summary for 7VC3
| Entry DOI | 10.2210/pdb7vc3/pdb |
| Descriptor | Prolyl-tRNA synthetase (ProRS), 4-[(3S)-3-cyclopropyl-3-(hydroxymethyl)-2-oxidanylidene-pyrrolidin-1-yl]-N-[[3-fluoranyl-5-(1-methylpyrazol-4-yl)phenyl]methyl]-6-methyl-pyridine-2-carboxamide, PROLINE, ... (9 entities in total) |
| Functional Keywords | protein translation, inhibitor, prs, atp pocket, double drug, ligase-ligase inhibitor complex, ligase/ligase inhibitor |
| Biological source | Toxoplasma gondii |
| Total number of polymer chains | 1 |
| Total formula weight | 59360.32 |
| Authors | Malhotra, N.,Yogavel, M.,Sharma, A. (deposition date: 2021-09-01, release date: 2022-09-07, Last modification date: 2023-11-29) |
| Primary citation | Yogavel, M.,Bougdour, A.,Mishra, S.,Malhotra, N.,Chhibber-Goel, J.,Bellini, V.,Harlos, K.,Laleu, B.,Hakimi, M.A.,Sharma, A. Targeting prolyl-tRNA synthetase via a series of ATP-mimetics to accelerate drug discovery against toxoplasmosis. Plos Pathog., 19:e1011124-e1011124, 2023 Cited by PubMed Abstract: The prolyl-tRNA synthetase (PRS) is a validated drug target for febrifugine and its synthetic analog halofuginone (HFG) against multiple apicomplexan parasites including Plasmodium falciparum and Toxoplasma gondii. Here, a novel ATP-mimetic centered on 1-(pyridin-4-yl) pyrrolidin-2-one (PPL) scaffold has been validated to bind to Toxoplasma gondii PRS and kill toxoplasma parasites. PPL series exhibited potent inhibition at the cellular (T. gondii parasites) and enzymatic (TgPRS) levels compared to the human counterparts. Cell-based chemical mutagenesis was employed to determine the mechanism of action via a forward genetic screen. Tg-resistant parasites were analyzed with wild-type strain by RNA-seq to identify mutations in the coding sequence conferring drug resistance by computational analysis of variants. DNA sequencing established two mutations, T477A and T592S, proximal to terminals of the PPL scaffold and not directly in the ATP, tRNA, or L-pro sites, as supported by the structural data from high-resolution crystal structures of drug-bound enzyme complexes. These data provide an avenue for structure-based activity enhancement of this chemical series as anti-infectives. PubMed: 36854028DOI: 10.1371/journal.ppat.1011124 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.973 Å) |
Structure validation
Download full validation report
